Credit Suisse Starts Fulgent Genetics (FLGT) at Outperform

Credit Suisse initiates coverage on Fulgent Genetics (NASDAQ: FLGT) with a Outperform rating and a price target of $13.00.

Analyst Erin Wilson commented, "FLGT is a rapidly-growing genetic testing company, leveraging a proprietary technology platform to provide physicians with relevant diagnostic information. Its analytics platform supports the broadest test menu (18,000+ genes) in the industry, and it performs tests at a low internal cost, a meaningful competitive advantage. It should gain share in a nascent genetic testing market while maintaining an attractive profit profile ahead of other genetic testing companies."

For an analyst ratings summary and ratings history on Fulgent Genetics click here. For more ratings news on Fulgent Genetics click here.

Shares of Fulgent Genetics closed at $8.88 yesterday.

You May Also Be Interested In

• Citi Upgrades Grupo Aeroportuario del Pacifico SAB de CV (GAPB:MM) (PAC) to Buy
• GE Aerospace (GE) PT Raised to $435 at UBS on Strong Demand
• UnitedHealth Group (UNH) PT Raised to $490 at UBS